SecBot SecBot
SECBOTREPLAY Home › Report › QURE

QURE · uniQure announced submission of a Biologics License Application (BLA)…

uniQure N.V. · 8-K filed Sep 2, 2026 at 07:06 ET

At the news

BULLISHIMPACT 7/10

8-K filed Sep 2, 2026 at 07:06 ET

uniQure announced submission of a Biologics License Application (BLA) to the FDA seeking accelerated approval of its gene therapy ifezuntirgene inilparvovec (AMT-130) for Huntington's disease, along with a parallel Marketing Authorisation Application (MAA) to the UK MHRA. The submissions are supported by three-year Phase I/II data showing slowed disease progression, and the company has requested priority review, which could shorten the FDA review cycle to six months. This is a major regulatory milestone for a first-in-class therapy addressing a large unmet need, though approval is not guaranteed and the stock has historically underperformed on high-impact events.

  • BLA submitted to FDA for accelerated approval of ifezuntirgene inilparvovec (AMT-130) for Huntington's disease
  • MAA submitted to UK MHRA for the same therapy
  • Priority review requested for the BLA; if granted, FDA review cycle would be six months after the 60-day filing review period
  • Submissions supported by three-year data from Phase I/II study showing slowing of disease progression vs. propensity score-matched external control

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access